CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.
äŒæ¥ã³ãŒãCVRX
äŒç€ŸåCVRx Inc
äžå Žæ¥Jun 30, 2021
æé«çµå¶è²¬ä»»è
ãCEOãHykes (Kevin)
åŸæ¥å¡æ°206
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jun 30
æ¬ç€Ÿæåšå°9201 West Broadway Avenue
éœåžMINNEAPOLIS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·55445
é»è©±çªå·17634162850
ãŠã§ããµã€ãhttps://www.cvrx.com/
äŒæ¥ã³ãŒãCVRX
äžå Žæ¥Jun 30, 2021
æé«çµå¶è²¬ä»»è
ãCEOãHykes (Kevin)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã